UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

April 26, 2019

Date of Report (Date of earliest event reported)

 

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

 


 

Illinois

 

1-2189

 

36-0698440

(State or other Jurisdiction

 

(Commission File Number)

 

(IRS Employer

of Incorporation)

 

 

 

Identification No.)

 


 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (224) 667-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   o

 

 

 


 

Item 5.07 — Submission of Matters to a Vote of Security Holders.

 

Abbott held its Annual Meeting of Shareholders on April 26, 2019.  The following is a summary of the matters voted on at that meeting.

 

(1)         The shareholders elected Abbott’s entire Board of Directors.  The persons elected to Abbott’s Board of Directors and the number of shares cast for, the number of shares withheld, and the number of broker non-votes, with respect to each of these persons, were as follows:

 

Name

 

Votes For

 

Votes Withheld

 

Broker Non-Votes

 

Robert J. Alpern, M.D.

 

1,362,626,534

 

8,937,377

 

226,477,994

 

Roxanne S. Austin

 

1,311,276,289

 

60,287,623

 

226,477,994

 

Sally E. Blount, Ph.D.

 

1,364,910,278

 

6,653,633

 

226,477,994

 

Michelle A. Kumbier

 

1,365,370,316

 

6,193,595

 

226,477,994

 

Edward M. Liddy

 

1,345,995,386

 

25,568,525

 

226,477,994

 

Nancy McKinstry

 

1,341,747,422

 

29,816,489

 

226,477,994

 

Phebe N. Novakovic

 

1,354,663,609

 

16,900,302

 

226,477,994

 

William A. Osborn

 

1,331,280,573

 

40,283,338

 

226,477,994

 

Samuel C. Scott III

 

1,336,757,852

 

34,806,059

 

226,477,994

 

Daniel J. Starks

 

1,359,372,353

 

12,191,558

 

226,477,994

 

John G. Stratton

 

1,365,072,138

 

6,491,773

 

226,477,994

 

Glenn F. Tilton

 

1,312,742,571

 

58,821,340

 

226,477,994

 

Miles D. White

 

1,304,663,575

 

66,900,336

 

226,477,994

 

 

(2)         The shareholders ratified the appointment of Ernst & Young LLP as Abbott’s auditors.  The number of shares cast in favor of the ratification of Ernst & Young LLP, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

1,558,328,371

 

36,811,567

 

2,901,968

 

0

 

 

(3)         The shareholders voted to approve the compensation of Abbott’s named executive officers listed in the proxy statement for the 2019 annual meeting, with 93.90 percent of the votes cast voting “For” the proposal.  The shareholder vote is advisory and non-binding. The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

1,288,000,766

 

73,743,985

 

9,819,161

 

226,477,994

 

 

2


 

(4)         The shareholders rejected a shareholder proposal requesting that Abbott’s Board of Directors adopt a policy that the Board Chairman be an independent director, with 19.86 percent of the votes cast voting “For” the proposal.  The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For

 

Against

 

Abstain

 

Broker Non-Votes

 

272,347,329

 

1,091,782,303

 

7,434,280

 

226,477,994

 

 

3


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

ABBOTT LABORATORIES

 

 

 

 

Date: April 30, 2019

By:

/s/ Brian B. Yoor

 

 

Brian B. Yoor

 

 

Executive Vice President, Finance

 

 

and Chief Financial Officer

 

4